Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-18
2006-07-18
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S019300, C514S119000, C514S423000, C514S626000
Reexamination Certificate
active
07078381
ABSTRACT:
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
REFERENCES:
patent: 4522752 (1985-06-01), Sisto et al.
patent: 5061811 (1991-10-01), Pinori et al.
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5783556 (1998-07-01), Clark et al.
patent: 5834428 (1998-11-01), Drucker
patent: 5952301 (1999-09-01), Drucker
patent: 6011155 (2000-01-01), Villhauer
patent: 6803357 (2004-10-01), Bachovchin et al.
patent: 19616486 (1997-10-01), None
patent: WO-89/03223 (1989-04-01), None
patent: WO-93/08259 (1993-04-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO-95/15309 (1995-06-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO-96/14857 (1996-05-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: 19616486 (1997-10-01), None
patent: WO-97/40832 (1997-11-01), None
patent: WO-98/19998 (1998-05-01), None
patent: WO-98/25644 (1998-06-01), None
patent: WO-00/10549 (2000-03-01), None
patent: WO-01/14318 (2001-03-01), None
patent: WO-01/34594 (2001-05-01), None
patent: WO-01/81337 (2001-11-01), None
Balkan et al. Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese zucker rats. Diabetologia Suppl. 40, A131 Abstract (1997).
Bell et al., 1983, “Exon duplication and divergence in the human preproglucagon gene”,Nature304 (5924):368-71.
Bell et al., 1983, “Hamster preproglucagon contains the sequence of glucagon and two related peptides”,Nature302(5910):716-8.
Conlon, 1988, “Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles”,Diabetolgia31(8):563-6.
Coruzzi et al., 1989, “Gastric antisecretory activity of telenzepine, a new MI-selective muscarinic antagonist: comparison with pirenzepine”,Arch Int Pharmacodyn Ther302:232-41.
Coutts et al. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. I. Variation of the P2 Position of Xaa-boroPro Dipeptides.J. Med. Chem. 39, 2087-2094 (1996).
Deacon et al.Diabetes. 1998. vol. 47, pp. 764-769.
Deacon et al., 1995, “Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects”,Diabetes44(9):1126-31.
Deacon et al. Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo.J. Clin. Endocrin. 83, 952-957 (1995).
Dupre, 1991, “Influences of the gut on the endocrine pancreas” The Endocrine Pancreas (Raven Press, New York) pp. 253-281.
Ebert et al., 1987, “Gastrointestinal peptides and insulin secretion”,DiabetesMet. Rev. 3:1-26.
Gutniak et al., 1992, “Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus”,N Engl J Med326(20):1316-22.
Habener et al., 1991, “Biosyntesies of glucagon” The Endocrine Pancreas (Raven Press, New York) pp. 53-71.
Holst, J. J. & Deacon, C.F. Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes.Diabetes47, 1663-1670 (1998).
Holst et al., 1987, “Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut”,FEBS Lett. 211(2):169-74.
Kawashima et al., 1990, “Pharmacological differentiation of presynaptic M1 muscarinic receptors modulating acetylcholine release from postsynaptic muscarinic receptors in guinea-pig ileum”,Gen Pharmacol21(1):17-21.
Kieffer et al. Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV,Endocrin. 136, 3585-3596 (1995).
Kinder et al., 1985, “Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase”.J Med Chem28(12):1917-25.
Kreymann et al., 1987, “Glucagon-like peptide-1 7-36: a physiological incretin in man”, Lancet 2(8571):1300-4.
Kubiak et al., 1994, “Metabolism or mouse growth hormone-releasing factor, mGRF(1-42)OH, and selected analogs from the bovine GRF series in mouse and bovine plasma in vitro”,Pept Res7(3):153-61.
Lambrecht et al., 1989, “Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists”,Trends Pharmacol Sci10(Suppl):60.
Lund et al., 1982, “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem”,Proc Natl Acad SciUSA 79(2):345-9.
Matteson et al., 1984, “Synthesis and properties of pinanediol ∀-amino boronic acids”,Organometallics3:1284.
Mentlein et al. Dipeptidyl-peptidase IV hydrolyses gastric Inhibitory polypeptide, glucagons-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.Eur. J. Biochem. 214, 829-835 (1993).
Mentlein et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV.Regulatory Peptides49, 133-144 (Dec. 10, 1993).
Mojsov et al., 1986, “Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing”,J Biol Chem261(25):11880-9.
Mojsov et al., 1987, “Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas”,J Clin Invest79(2):616-9.
Mojsov, 1992, “Structural requirements for biological activity of glucagon-like peptide-I”,Int J Pept Protein Res40(3-4):333-43.
Orskov et al., 1987, “Pancreatic and intestinal processing of proglucagon in man,”Diabetologia30(11):874-81.
Patzelt et al., 1979, “Identification and processing of proglucagon in pancreatic islets”,Nature282(5736):260-6.
Pederson et al. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Adminstration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide.Diabetes47, 1253-1258 (Aug. 1998).
Pospisilik, John A. et al. Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26).Regulatory Peptides96, 133-141, 2001.
Radhakrishna et al., 1979, “New method for direct conversion of amides to amines”,J Org Chem44:1746.
Schmidt et al., 1985, “Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic Islets ”,Diabetologia28(9):704-7.
Shue et al., 1987, “Amide bond surrogates: a general synthetic route to trans carbon—carbon double bond isosteres”,Tetrahedron Letters28:3225.
Stanely et al., 1989, “Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats”,Physiol Behav46(2):173-7.
Weir et al., 1989, “Glucagonlike peptide I (7-37) actions on endocrine pancrease”,Diabetes38(3):338-42.
Wilding et al., 1992, “Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats”,J Endocrinol132(2):299-304.
Bachovchin William W.
Drucker Daniel
Plaut Andrew G.
Foley & Hoag LLP
Gordon Dana M.
Russel Jeffrey Edwin
Trustees of Tufts College
LandOfFree
Method of regulating glucose metabolism, and reagents... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of regulating glucose metabolism, and reagents..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of regulating glucose metabolism, and reagents... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582602